Recombinant
RabMAb

Recombinant Anti-Cytokeratin 13 antibody [EPR3671] (HRP) (ab199092)

Overview

  • Product name

    Anti-Cytokeratin 13 antibody [EPR3671] (HRP)
    See all Cytokeratin 13 primary antibodies
  • Description

    Rabbit monoclonal [EPR3671] to Cytokeratin 13 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide within Human Cytokeratin 13 aa 100-200. The exact sequence is proprietary.
    (Peptide available as ab180923)

  • Positive control

    • WB: A431 whole cell lysate. IHC-P: FFPE human tonsil (normal) tissue sections.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab199092 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 50 kDa (predicted molecular weight: 50 kDa).Can be blocked with Cytokeratin 13 peptide (ab180923).
IHC-P 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Tissue specificity

    Expressed in some epidermal sweat gland ducts (at protein level) and in exocervix, esophagus and placenta.
  • Involvement in disease

    Defects in KRT13 are a cause of white sponge nevus of cannon (WSN) [MIM:193900]. WSN is a rare autosomal dominant disorder which predominantly affects non-cornified stratified squamous epithelia. Clinically, it is characterized by the presence of soft, white, and spongy plaques in the oral mucosa. The characteristic histopathologic features are epithelial thickening, parakeratosis, and vacuolization of the suprabasal layer of oral epithelial keratinocytes. Less frequently the mucous membranes of the nose, esophagus, genitalia and rectum are involved.
  • Sequence similarities

    Belongs to the intermediate filament family.
  • Post-translational
    modifications

    O-glycosylated; glycans consist of single N-acetylglucosamine residues.
  • Information by UniProt
  • Database links

  • Alternative names

    • 47 kDa cytokeratin antibody
    • CK-13 antibody
    • CK13 antibody
    • Cytokeratin 13 antibody
    • Cytokeratin-13 antibody
    • K13 antibody
    • K1C13_HUMAN antibody
    • Ka13 antibody
    • Keratin 13 antibody
    • Keratin antibody
    • keratin type I cytoskeletal 13 antibody
    • Keratin-13 antibody
    • Krt-1.13 antibody
    • Krt1-13 antibody
    • KRT13 antibody
    • MGC161462 antibody
    • MGC3781 antibody
    • type I cytoskeletal 13 antibody
    • Type I keratin Ka13 antibody
    • WSN2 antibody
    see all

Images

  • IHC image of Cytokeratin 13 staining in a section of formalin-fixed paraffin-embedded normal human tonsil tissue*, performed on a Leica BONDTM. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab199092, 1/100 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • Anti-Cytokeratin 13 antibody [EPR3671] (HRP) (ab199092) at 1/5000 dilution + A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 50 kDa
    Observed band size: 50 kDa


    Exposure time: 10 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab199092 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab199092 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab199092.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up